Clinical Trial Update: The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated autologous tolerogenic dendritic cells as a treatment for Type 1 diabetes mellitus; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Autologous tolerogenic dendritic cells

Snippet

Sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Conditions: Diabetes Mellitus | Phase 1, Phase 2 | Status: COMPLETED